Now, a study led by the University of Barcelona reveals that the functional assay dynamic BH3 profiling (DBP) can predict whether this treatment will be effective in these cancer patients and thus ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients show molecular alterations in the ALK gene involved in cell multiplication.